Viome Precision Nutritional Programs to Improve Clinical Outcomes for Mental Health Conditions

Not Applicable

Recruiting

• Conditions: Mental Health Disorder; Anxiety State; Mental Health; Depression, Anxiety; Anxiety Disorders; Mental Health Issue; Anxiety; Anxiety Depression; Depression

• Registration Number: NCT06190184
• Lead Sponsor: Viome

Brief Summary

US residents who have obesity and sign the informed consent form and are screened and enrolled for this study. Participants who are enrolled complete a survey upon enrollment and are randomized into one of two arms. This study is direct to participant and will not utilize clinical sites.

Detailed Description

Participants who meet the eligibility criteria are randomized into any of the two arms including: the placebo arm or the VIOME Precision Nutrition Program (VPNP) arm.

Placebo and Viome's Precision Nutrition Program include supplements and/or dietary recommendations towards improving the symptoms associated with metabolic wellness. The trial will last approximately 4 months for each participant.

Study Timeline

• Study Start: 2023-10-26
• Study First Submitted: 2023-12-08
• Status Verified: 2024-01
• Study First Submitted QC: 2024-01-03
• Last Update Submitted: 2024-01-03
• Study First Posted: 2024-01-05
• Last Update Posted: 2024-01-05
• Primary Completion: 2024-10-31
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Resident of the United States
• 50 years old and older OR BMI of 25 or greater
• Able to speak and read English
• No unexplained weight loss, fevers, anemia, or blood in stool
• Willing and able to follow the trial instructions, as described in the recruitment letter
• Signed and dated informed consent prior to any trial-specific procedures.
• PHQ9 score of 5-24 (inclusive)

Exclusion Criteria

• Unwilling to change their current diet

• Prior use of Viome products or services

• Antibiotic use in the previous 4 weeks

• Pregnancy (current or planned in the next 4 months)

• < 90 days postpartum

• Breast feeding

• Active infection

• Unable or unwilling to use Viome's App on an iPhone or Android smartphone

• Significant diet or lifestyle change in the previous 1 month

• IBD diagnosis -Major psychiatric/DSM-4 disease diagnosis (e.g. Schizophrenia, Bipolar disorder, Post- traumatic Stress Disorder, Obsessive Compulsive disorder)

• Use of investigational drugs, products or devices within 1 month prior to and 4 months after the start of the trial

• Cancer therapy within the previous 1 year

• Major surgery in the last 6 months or planned in the next 4 months

• Allergies to any supplement ingredients listed in the screening survey

• Currently on a specific diet: FODMAP, KETO, PALEO

• Answered yes to the question, "In the past few weeks, have you wished you were dead or had thoughts about killing yourself?"

• Gastrointestinal disease including:

  • GI surgery except:

    • Appendectomy and benign polypectomy

• Esophagitis

• Celiac disease

• GI malignancy or obstruction

• Peptic Ulcer Disease

• Duodenal or gastric ulcer disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Change in GAD-7 Score	4 months	Change in GAD-7 score for VPNP group compared to baseline scores.
Change in Quality of Life Score	4 months	Change in quality of life score for VPNP group compared to baseline scores.
Change in PHQ-9 Score	4 months	Change in PHQ-9 score for VPNP group compared to baseline scores.
Change in Perceived Stress Scale Score	4 months	Change in perceived stress score for VPNP group compared to baseline scores.

Trial Locations

Locations (1)

Viome Life Sciences; 🇺🇸 Bothell, Washington, United States